Stereotactic radiosurgery for brain metastasis from gynecological malignancies
MetadataShow full item record
CitationKasper, Ekkehard, Franziska Ippen, Eric Wong, Eric Uhlmann, Scott Floyd, and Anand Mahadevan. 2017. “Stereotactic radiosurgery for brain metastasis from gynecological malignancies.” Oncology Letters 13 (3): 1525-1528. doi:10.3892/ol.2017.5621. http://dx.doi.org/10.3892/ol.2017.5621.
AbstractBrain metastases are relatively uncommon in gynecological malignancies, and there is limited available data on their management. The present study reports the outcomes of patients with brain metastasis from gynecological malignancies who were treated with stereotactic radiosurgery (SRS). Patients with brain metastasis from a gynecological primary site were treated with SRS using the Cyberknife™ frameless SRS system. Primary lesions were treated with a single fraction of 16–22 Gy. A total of 3 resection cavities were treated with 8 Gy 3 times, meaning a total of 24 Gy, and 1 recurrent lesion was re-irradiated with 5 Gy 5 times, meaning a total of 25 Gy. All patients were followed up with regular magnetic resonance imaging and clinical examinations 1 month after treatment and every 2 months thereafter. A total of 20 lesions in 8 patients were included in this study; 1 patient presented with metastatic endometrial cancer and the remaining 7 presented with metastatic ovarian cancer. The median age was 61 years (range, 48–78 years). All patients had received systemic therapy prior to developing brain metastasis. A total of 3 patients underwent surgical resection and 1 patient was administered re-irradiation for recurrence. There were 3 local failures in 2 patients. The actuarial 1-, 2- and 3-year local control rates were 91, 91 and 76%, respectively. The median overall survival time was 29 months. No SRS-associated toxicities or neurological mortalities were observed. In conclusion, brain metastasis from gynecological malignancies is uncommon, however, SRS is a safe and effective treatment modality for local control as a primary or adjuvant treatment in patients with this disease.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32630531
- HMS Scholarly Articles